Dendrite's Flagship Sales Force Effectiveness Solution Available on Microsoft SQL Server
July 24 2006 - 8:00AM
Business Wire
Dendrite International, Inc. (NASDAQ:DRTE) a leading provider of
pharmaceutical industry solutions, today announced that it will
make its flagship sales force effectiveness solution, Mobile
Intelligence(TM), available on Microsoft SQL Server 2005 in the
fourth quarter. This strategic decision was made to provide its
customers with additional options that may result in a lower total
cost of ownership. Dendrite's Mobile Intelligence incorporates a
revolutionary, human-centered design that mirrors the workflow of
the representative. It enables users to be more efficient and
effective in their detailing activity by providing access to all
the information they require on a customer call with a few
keystrokes. By developing Mobile intelligence using Microsoft .NET
technologies, one of the world's most widely accepted development
environments, Dendrite has ensured maximum flexibility for
integration into its customers' existing infrastructure while
reducing total cost of ownership. "Dendrite's objective is to
enable a wide range of pharmaceutical companies to capitalize on
our solutions for competitive advantage," said Mark Theilken,
Dendrite's president of Sales Solutions. "The global pharmaceutical
industry is evolving rapidly and every company has unique
circumstances that require a flexible, adaptable solution set. Our
latest version of Mobile Intelligence ensures that a wider universe
of pharmaceutical companies, regardless of size or geography, can
benefit from this flexibility." "SQL Server 2005 is a
well-established and proven technology in the pharmaceutical
market," said Steve Shihadeh, general manager, healthcare and life
sciences, Microsoft. "Dendrite's innovative use of Microsoft
technology provides seamless integration with desktop applications,
enabling users to better connect and collaborate, ultimately
allowing them to make more informed business decisions." About
Dendrite Founded in 1986, Dendrite International (NASDAQ: DRTE)
enables sales, marketing, clinical and compliance solutions for the
global pharmaceutical industry. The company's clients are located
in more than 50 countries and include the world's top 20
pharmaceutical companies. For more information, please visit
www.dendrite.com. Note: Dendrite and the Dendrite product names
mentioned herein are the trademarks or registered trademarks of
Dendrite International, Inc. The names of other companies or
products mentioned herein may be the trademarks of their respective
owners. This document may contain forward-looking statements that
may be identified by such forward-looking terminology as "expect,"
"believe," "anticipate," "will," "intend," "plan," "target,"
"outlook," "guidance," and similar statements or variations. Such
forward-looking statements are based on our current expectations,
estimates, assumptions and projections and involve significant
risks and uncertainties, including risks which may result from our
dependence on the pharmaceutical industry; fluctuations in
quarterly revenues due to lengthy sales and implementation cycles
for certain of our solutions; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers; changes in demand for our
products and services attributable to any weakness experienced in
the economy or mergers, acquisitions and consolidations in the
pharmaceutical industry; successful and timely development and
introduction of new products and versions; rapid technological
changes; increased competition; international operations;
integrating the entities we acquire; our ability to effectively
manage our growth; the protection of our proprietary technology;
our ability to compete in the Internet-related products and
services market; the continued demand for Internet-related products
and services; the ability of our third party vendors to respond to
technological change; our ability to maintain our relationships
with third-party vendors; less favorable than anticipated results
from strategic relationships; dependence of data solutions on
strategic relationships; events which may affect the U.S. and world
economies; and catastrophic events which could negatively affect
our information technology infrastructure. Other important factors
that should be reviewed and carefully considered are included in
the company's 10-K, 10-Qs, and other reports filed with the SEC.
Actual results may differ materially. The company assumes no
obligation for updating any such forward-looking statements to
reflect actual results, changes in assumptions or other changes
affecting such forward-looking statements.
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Dendrite (NASDAQ:DRTE)
Historical Stock Chart
From Aug 2023 to Aug 2024